

Genetic and Pharmacological Inhibition of Galectin-3 Promotes Myocardial Protection by Interfering With Myocardial Fibrogenesis

Circulation: Heart Failure

6, 107-117

DOI: [10.1161/circheartfailure.112.971168](https://doi.org/10.1161/circheartfailure.112.971168)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 501-515.	1.1	64
2	Cardiac oxidative stress in a mouse model of neutral lipid storage disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 1600-1608.	1.2	25
3	Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. <i>International Journal of Cardiology</i> , 2013, 169, 177-182.	0.8	76
4	Galectin-3 in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2013, 15, 1095-1101.	2.9	90
5	The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers. <i>Current Heart Failure Reports</i> , 2013, 10, 441-449.	1.3	27
6	Galectin-3, new potential therapeutic target for cardiac remodelling. <i>European Journal of Heart Failure</i> , 2013, 15, 709-709.	2.9	0
7	Anesthetic regimen for cardiac function evaluation by echocardiography in mice: comparison between ketamine, etomidate and isoflurane versus conscious state. <i>Laboratory Animals</i> , 2013, 47, 284-290.	0.5	29
8	Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 219-226.	1.6	179
9	Galectin-3: a new biomarker for heart failure progression and prognosis. <i>Laboratoriums Medizin</i> , 2013, 37, 251-260.	0.1	1
10	Letter by Januzzi Regarding Article, "Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction". <i>Circulation: Heart Failure</i> , 2013, 6, e57.	1.6	0
11	Statins in heart failure: not yet the end of the story?. <i>European Journal of Heart Failure</i> , 2013, 15, 708-709.	2.9	4
12	The complex role of bone turnover biomarkers in cardiovascular diseases. <i>European Journal of Heart Failure</i> , 2013, 15, 709-710.	2.9	0
13	Labeling galectin-3 for the assessment of myocardial infarction in rats. <i>EJNMMI Research</i> , 2014, 4, 75.	1.1	6
14	Functions of Galectin-3 and Its Role in Fibrotic Diseases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 336-343.	1.3	209
15	Plasma galectin 3 and heart failure risk in the physicians' health study. <i>European Journal of Heart Failure</i> , 2014, 16, 350-354.	2.9	37
16	Emerging Biomarkers in Heart Failure and Cardiac Cachexia. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23878-23896.	1.8	36
17	Renal Handling of Galectin-3 in the General Population, Chronic Heart Failure, and Hemodialysis. <i>Journal of the American Heart Association</i> , 2014, 3, e000962.	1.6	46
18	Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e000962.	0.7	39

#	ARTICLE	IF	CITATIONS
19	The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 257-266.	1.5	33
20	Galectin-3 in diabetic patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1413-23.	1.4	58
22	The NTR domain of procollagen C-proteinase enhancer-1 (PCPE-1) mediates PCPE-1 binding to syndecans-1, -2 and -4 as well as fibronectin. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 57, 45-53.	1.2	13
23	Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H361-H369.	1.5	35
24	Galectin-3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	116
25	Mechanisms of persistent atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2014, 29, 20-27.	0.8	70
26	Comprehensive Review of the Prognostic Value of Galectin-3 in Heart Failure. <i>Cardiology in Review</i> , 2014, 22, 171-175.	0.6	26
27	Developing Therapies for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2014, 2, 97-112.	1.9	267
28	Soluble ST2 and Galectin-3 in Heart Failure. <i>Clinics in Laboratory Medicine</i> , 2014, 34, 87-97.	0.7	32
29	Galectin-3 expression in cardiac remodeling after myocardial infarction. <i>International Journal of Cardiology</i> , 2014, 172, e98-e101.	0.8	51
30	Using galectin-3 to reduce heart failure rehospitalization. <i>Future Cardiology</i> , 2014, 10, 221-227.	0.5	4
31	Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation. <i>Cardiology Clinics</i> , 2014, 32, 637-650.	0.9	7
32	Differences in Cell-Type-Specific Responses to Angiotensin II Explain Cardiac Remodeling Differences in C57BL/6 Mouse Substrains. <i>Hypertension</i> , 2014, 64, 1040-1046.	1.3	22
33	Novel Biomarkers in Heart Failure with Preserved Ejection Fraction. <i>Heart Failure Clinics</i> , 2014, 10, 471-479.	1.0	17
34	Galectin-3: A Modifiable Risk Factor in Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 237-246.	1.3	63
35	Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. <i>Cardiovascular Research</i> , 2014, 103, 268-280.	1.8	98
36	Galectin 3: Newest Marker of HF Outcomes. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 112.	0.6	3
37	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. <i>American Heart Journal</i> , 2014, 167, 853-860.e4.	1.2	128

#	ARTICLE	IF	CITATIONS
38	Galectin 3 and incident atrial fibrillation in the community. <i>American Heart Journal</i> , 2014, 167, 729-734.e1.	1.2	101
39	Biomarkers for Risk Prediction in Acute Decompensated Heart Failure. <i>Current Heart Failure Reports</i> , 2014, 11, 246-259.	1.3	16
40	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 260-268.	1.9	104
41	Influence of dipyridamole stress echocardiography on galectin-3, amino-terminal B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T. <i>Acta Cardiologica</i> , 2014, 69, 377-383.	0.3	3
42	Galectin-3 in patients undergoing ablation of atrial fibrillation. <i>IJC Metabolic & Endocrine</i> , 2014, 5, 56-60.	0.5	11
43	Cardiac α -LXR protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization. <i>EMBO Molecular Medicine</i> , 2015, 7, 1229-1243.	3.3	58
44	Effects of anesthesia on conventional and speckle tracking echocardiographic parameters in a mouse model of pressure overload. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1679-1687.	0.8	4
45	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. <i>European Journal of Heart Failure</i> , 2015, 17, 764-771.	2.9	109
46	Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. <i>European Journal of Heart Failure</i> , 2015, 17, 1271-1282.	2.9	55
47	Galectin-3 in heart failure pathology – another brick in the wall. <i>Acta Cardiologica</i> , 2015, 70, 323-331.	0.3	23
48	Biomarkers in Acute Decompensated Heart Failure. <i>Clinical Medicine Insights Therapeutics</i> , 2015, 7, CMT.S18476.	0.4	0
49	The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists. <i>PLoS ONE</i> , 2015, 10, e0119160.	1.1	18
50	Galectin-3 in Patients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation. <i>PLoS ONE</i> , 2015, 10, e0123574.	1.1	45
51	Macrophages and galectin 3 play critical roles in CVB3-induced murine acute myocarditis and chronic fibrosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 85, 58-70.	0.9	67
52	Long-term biological variability of galectin-3 after heart transplantation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 119-23.	1.4	2
53	Plasma galectin-3 predicts clinical outcomes after catheter ablation in persistent atrial fibrillation patients without structural heart disease. <i>Europace</i> , 2015, 17, 1541-1547.	0.7	43
54	Galectin-3 and incident heart failure among patients with pre-existing coronary artery disease: The ADVANCE study. <i>Clinical Trials and Regulatory Science in Cardiology</i> , 2015, 5, 1-7.	1.0	1
55	Pharmacological inhibition of galectin-3 protects against hypertensive nephropathy. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, F500-F509.	1.3	42

#	ARTICLE	IF	CITATIONS
56	Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling. , 2015, , 105-116.		0
57	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2015, 184, 96-100.	0.8	60
58	The Association of Serum Galectin-3 Levels with Atrial Electrical and Structural Remodeling. Journal of Cardiovascular Electrophysiology, 2015, 26, 635-640.	0.8	63
59	Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 513-521.	1.9	70
60	Early microlesion of viral encephalitis confirmed by galectin-3 expression after a virus inoculation. Neuroscience Letters, 2015, 592, 107-112.	1.0	18
61	Circulating Biomarkers of Myocardial Fibrosis. Journal of the American College of Cardiology, 2015, 65, 2449-2456.	1.2	196
62	Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension, 2015, 66, 767-775.	1.3	129
63	Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms. International Journal of Cardiology, 2015, 201, 429-437.	0.8	25
64	Galectin-3 and post-myocardial infarction cardiac remodeling. European Journal of Pharmacology, 2015, 763, 115-121.	1.7	63
65	Galectin-3 in Atrial Fibrillation: A Novel Marker of Atrial Remodeling or Just Bystander?. American Journal of Cardiology, 2015, 116, 163.	0.7	5
66	Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. Herz, 2015, 40, 788-794.	0.4	14
67	Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. European Journal of Heart Failure, 2015, 17, 385-392.	2.9	54
68	Galectin-3 in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2015, 3, 245-252.	1.9	49
69	The Inflammatory Hypothesis of Atrial Fibrillation: Diagnostic Marker, Therapeutic Target, or Innocent Bystander?. Journal of Cardiovascular Electrophysiology, 2015, 26, 641-643.	0.8	2
70	Galectin-3 in atrial fibrillation: Simple bystander, player or both?. Clinical Biochemistry, 2015, 48, 818-822.	0.8	27
71	Lack of Galectin-3 Prevents Cardiac Fibrosis and Effective Immune Responses in a Murine Model of <i>Trypanosoma cruzi</i> Infection. Journal of Infectious Diseases, 2015, 212, 1160-1171.	1.9	45
72	State of the Art: Newer biomarkers in heart failure. European Journal of Heart Failure, 2015, 17, 559-569.	2.9	151
73	Developments in the management of Chagas cardiomyopathy. Expert Review of Cardiovascular Therapy, 2015, 13, 1393-1409.	0.6	66

#	ARTICLE	IF	CITATIONS
74	The Current and Potential Clinical Relevance of Heart Failure Biomarkers. <i>Current Heart Failure Reports</i> , 2015, 12, 318-327.	1.3	10
75	Associations between circulating proteins and corresponding genes expressed in coronary thrombi in patients with acute myocardial infarction. <i>Thrombosis Research</i> , 2015, 136, 1240-1244.	0.8	6
76	Mineralocorticoid Receptor Antagonists Modulate Galectin-3 and Interleukin-33/ST2 Signaling in Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction. <i>JACC: Heart Failure</i> , 2015, 3, 50-58.	1.9	77
77	The Impact of Galectin-3 Inhibition on Aldosterone-Induced Cardiac and Renal Injuries. <i>JACC: Heart Failure</i> , 2015, 3, 59-67.	1.9	164
78	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. <i>Clinica Chimica Acta</i> , 2015, 443, 29-38.	0.5	70
79	Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats. <i>British Journal of Pharmacology</i> , 2015, 172, 1494-1504.	2.7	84
80	Relationship of galectin-3 to left ventricular geometry and hypertrophy in chronic hemodialysis patients. <i>Herz</i> , 2015, 40, 702-708.	0.4	9
81	Galectin-3 and heart failure: Prognosis, prediction & clinical utility. <i>Clinica Chimica Acta</i> , 2015, 443, 48-56.	0.5	56
82	Galectin-3: an emerging all-out player in metabolic disorders and their complications. <i>Glycobiology</i> , 2015, 25, 136-150.	1.3	94
83	Is Elevated Circulating Galectin-3 Level A Predictor of Pulmonary Artery Hypertension Development and Progression?. <i>Clinical & Medical Biochemistry Open Access</i> , 2016, 2, .	0.1	2
84	Elevated galectin-3 level predicts pulmonary artery hypertension. <i>Biological Markers and Guided Therapy</i> , 0, 3, 89-97.	0.1	2
85	Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging. <i>Disease Markers</i> , 2016, 2016, 1-9.	0.6	4
86	Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction. <i>Disease Markers</i> , 2016, 2016, 1-6.	0.6	4
87	The Role of Galectin-3 in the Kidneys. <i>International Journal of Molecular Sciences</i> , 2016, 17, 565.	1.8	88
88	Procollagen C-Proteinase Enhancer 1 (PCPE-1) as a Plasma Marker of Muscle and Liver Fibrosis in Mice. <i>PLoS ONE</i> , 2016, 11, e0159606.	1.1	18
89	Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway. <i>Frontiers in Pharmacology</i> , 2016, 7, 495.	1.6	11
90	Role for Galectin-3 in Calcific Aortic Valve Stenosis. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	55
91	Serial galectin-3 and future cardiovascular disease in the general population. <i>Heart</i> , 2016, 102, 1134-1141.	1.2	42

#	ARTICLE	IF	CITATIONS
92	Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction. <i>Acta Cardiologica</i> , 2016, 71, 191-197.	0.3	26
93	Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes. <i>JACC Basic To Translational Science</i> , 2016, 1, 143-154.	1.9	99
94	Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. <i>Progress in Neurobiology</i> , 2016, 142, 23-44.	2.8	494
95	Drug Treatment of Hypertension: Focus on Vascular Health. <i>Drugs</i> , 2016, 76, 1529-1550.	4.9	53
96	Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction. <i>JACC: Heart Failure</i> , 2016, 4, 847-856.	1.9	23
97	Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure. <i>Current Heart Failure Reports</i> , 2016, 13, 207-218.	1.3	17
98	Authors' Reply. <i>American Journal of Pathology</i> , 2016, 186, 2234-2235.	1.9	0
99	Utility of galectin-3 in predicting post-infarct remodeling after acute myocardial infarction based on extracellular volume fraction mapping. <i>International Journal of Cardiology</i> , 2016, 223, 458-464.	0.8	19
100	Cardiac dysfunction in Pkd1-deficient mice with phenotype rescue by galectin-3 knockout. <i>Kidney International</i> , 2016, 90, 580-597.	2.6	25
101	Galectin-3 Predicts Left Ventricular Remodeling of Hypertension. <i>Journal of Clinical Hypertension</i> , 2016, 18, 506-511.	1.0	25
102	Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	145
103	New onset atrial fibrillation is associated with elevated galectin-3 levels. <i>International Journal of Cardiology</i> , 2016, 223, 48-49.	0.8	19
104	Novel biomarkers predicting cardiac function after acute myocardial infarction. <i>British Medical Bulletin</i> , 2016, 119, 63-74.	2.7	23
105	Galectin-3, Cardiac Function, and Fibrosis. <i>American Journal of Pathology</i> , 2016, 186, 2232-2234.	1.9	15
106	Relationship of galectin-3 with obesity, IL-6, and CRP in women. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1435-1443.	1.8	27
107	Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H1287-H1296.	1.5	48
108	Dynamics and prognostic role of galectin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 138.	0.7	28
109	Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. <i>Clinica Chimica Acta</i> , 2016, 457, 99-105.	0.5	26

#	ARTICLE	IF	CITATIONS
110	Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development. <i>Cardiovascular Research</i> , 2016, 111, 217-226.	1.8	24
111	Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. <i>Hypertension</i> , 2016, 67, 606-612.	1.3	90
112	Galectin-3, osteopontin and successful aging. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 873-7.	1.4	10
113	Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 77-83.	2.5	66
114	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	93
115	New Targets in the Drug Treatment of Heart Failure. <i>Drugs</i> , 2016, 76, 187-201.	4.9	2
116	Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. <i>Clinica Chimica Acta</i> , 2016, 452, 50-57.	0.5	33
117	Early cardiac changes induced by a hypercaloric Western-type diet in "subclinical" obesity. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 310, H655-H666.	1.5	28
118	Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis. <i>American Journal of Pathology</i> , 2016, 186, 1114-1127.	1.9	75
119	Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. <i>Angiology</i> , 2016, 67, 854-859.	0.8	24
120	The fibrosis-cell death axis in heart failure. <i>Heart Failure Reviews</i> , 2016, 21, 199-211.	1.7	214
121	Galectin-3: A potential new target for upstream therapy of atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 203, 1131-1132.	0.8	2
122	The emerging role of galectins in cardiovascular disease. <i>Vascular Pharmacology</i> , 2016, 81, 31-41.	1.0	34
123	Reply to Novaes et al. <i>Journal of Infectious Diseases</i> , 2016, 213, 871.2-873.	1.9	0
124	Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications. <i>Canadian Journal of Cardiology</i> , 2016, 32, 659-668.	0.8	298
125	Novel Upstream Approaches to Prevent Atrial Fibrillation Perpetuation. <i>Heart Failure Clinics</i> , 2016, 12, 309-322.	1.0	8
126	LXR β improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes. <i>Diabetologia</i> , 2016, 59, 634-643.	2.9	33
127	CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases. <i>Pancreatology</i> , 2016, 16, 115-120.	0.5	18

#	ARTICLE	IF	CITATIONS
128	Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 93, 175-185.	0.9	209
129	Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 203, 398-406.	0.8	13
130	Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. <i>Heart and Vessels</i> , 2016, 31, 939-946.	0.5	51
131	Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. <i>Current Heart Failure Reports</i> , 2017, 14, 106-116.	1.3	16
132	Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin β 2 chain-deficient muscular dystrophy. <i>Scientific Reports</i> , 2017, 7, 44059.	1.6	15
133	Galectin-3 Levels Are Elevated and Predictive of Mortality in Pulmonary Hypertension. <i>Heart Lung and Circulation</i> , 2017, 26, 1208-1215.	0.2	31
134	Galectin-3 in acute coronary syndrome. <i>Clinical Biochemistry</i> , 2017, 50, 797-803.	0.8	66
135	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
136	Fibrosis and Fibrotic Gene Expression in Pediatric and Adult Patients With Idiopathic Dilated Cardiomyopathy. <i>Journal of Cardiac Failure</i> , 2017, 23, 314-324.	0.7	28
137	Cardiac Fibrosis and Arrhythmogenesis. , 2017, 7, 1009-1049.		97
138	Traditional Chinese medicine baixin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1900-1906.	0.8	12
139	Macrophages take centre stage in the heartâ€œbrainâ€œkidney axis. <i>Nature Reviews Nephrology</i> , 2017, 13, 388-390.	4.1	8
140	The Predictive Value of Plasma Galectin-3 for Ards Severity and Clinical Outcome. <i>Shock</i> , 2017, 47, 331-336.	1.0	23
141	A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. <i>Clinical Science</i> , 2017, 131, 935-949.	1.8	19
142	Circulating Biomarkers of Cardiac Fibrosis. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	8
143	Association of Cardiac Galectin-3 Expression, Myocarditis, and Fibrosis in Chronic Chagas Disease Cardiomyopathy. <i>American Journal of Pathology</i> , 2017, 187, 1134-1146.	1.9	43
144	Procollagen C-proteinase enhancer 1 (PCPE-1) functions as an anti-angiogenic factor and enhances epithelial recovery in injured cornea. <i>Cell and Tissue Research</i> , 2017, 370, 461-476.	1.5	13
145	Fibrosis-Related Gene Expression in Single Ventricle Heart Disease. <i>Journal of Pediatrics</i> , 2017, 191, 82-90.e2.	0.9	14

#	ARTICLE	IF	CITATIONS
146	From Inflammation to Fibrosisâ€”Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities. <i>Current Heart Failure Reports</i> , 2017, 14, 235-250.	1.3	222
147	Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 673-683.e3.	2.3	31
148	Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 261-270.	1.0	4
149	Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During) Tj ETQq1 1 0.784314rgBT /Overlock 10	1.0	10
150	Role of galectin-3 in autoimmune and non-autoimmune nephropathies. <i>Autoimmunity Reviews</i> , 2017, 16, 34-47.	2.5	43
151	Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. <i>Archives of Medical Science</i> , 2017, 4, 897-913.	0.4	48
152	Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 947.	1.8	8
153	GALECTIN-3: A NOVEL BIOMARKER FOR THE PROGNOSIS OF HEART FAILURE. <i>Medicine and Pharmacy Reports</i> , 2017, 90, 129-132.	0.2	27
154	Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 973.	1.8	33
155	Therapeutic inhibition of galectinâ€™3 improves cardiomyocyte apoptosis and survival during heart failure. <i>Molecular Medicine Reports</i> , 2017, 17, 4106-4112.	1.1	13
156	Is galectin-3 a promoter of ventricular dysfunction?. <i>Romanian Journal of Laboratory Medicine</i> , 2018, 26, 21-36.	0.1	2
157	Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. <i>Clinical Science</i> , 2018, 132, 1471-1485.	1.8	37
158	Evaluation of serum procollagen C-proteinase enhancer 1 level as a fibrosis marker in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 918-924.	0.8	6
159	Biomarkers for heart failure: small molecules with high clinical relevance. <i>Journal of Internal Medicine</i> , 2018, 283, 530-543.	2.7	87
160	Novel heart failure biomarkers: why do we fail to exploit their potential?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 246-263.	2.7	67
161	The effects of galectinâ€™3 depletion apheresis on induced skin inflammation in a porcine model. <i>Journal of Clinical Apheresis</i> , 2018, 33, 486-493.	0.7	5
162	Ticagrelor attenuates myocardial ischaemiaâ€™reperfusion injury possibly through downregulating galectinâ€™3 expression in the infarct area of rats. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1180-1186.	1.1	24
163	Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus. <i>Diabetologia</i> , 2018, 61, 1212-1219.	2.9	59

#	ARTICLE	IF	CITATIONS
164	Galectin-3 in patients with coronary heart disease and atrial fibrillation. <i>Clinica Chimica Acta</i> , 2018, 478, 166-170.	0.5	21
165	Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 452-467.	4.0	62
166	Galectin-3 in the fibrotic response: Cellular targets and molecular mechanisms. <i>International Journal of Cardiology</i> , 2018, 258, 226-227.	0.8	9
167	Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients. <i>Angiology</i> , 2018, 69, 449-455.	0.8	10
168	Galectin-3 in Heart Failure. <i>Heart Failure Clinics</i> , 2018, 14, 75-92.	1.0	86
169	OBSOLETE: Biomarkers in Heart Failure, Use of. , 2018, , .		0
170	Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities. <i>Mediators of Inflammation</i> , 2018, 2018, 1-11.	1.4	44
171	Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3246-3254.	1.2	51
172	Activation of TGF- β 1/ α 1-SMA/Col I Profibrotic Pathway in Fibroblasts by Galectin-3 Contributes to Atrial Fibrosis in Experimental Models and Patients. <i>Cellular Physiology and Biochemistry</i> , 2018, 47, 851-863.	1.1	55
173	Biomarkers in Heart Failure, Use of. , 2018, , 293-302.		0
174	IL (Interleukin)-10 α -STAT3 β -Galectin-3 Axis Is Essential for Osteopontin-Producing Reparative Macrophage Polarization After Myocardial Infarction. <i>Circulation</i> , 2018, 138, 2021-2035.	1.6	138
175	Inflammatory Mediators in Heart Failure. , 2018, , 33-50.		0
176	Galectin-3 in the pathogenesis of heart failure: a causative mediator or simply a biomarker?. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H1256-H1258.	1.5	4
177	Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β ₂ -adrenoceptor overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 314, H1169-H1178.	1.5	23
178	Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. <i>Theranostics</i> , 2018, 8, 593-609.	4.6	187
179	Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. <i>Archives of Medical Science</i> , 2018, 14, 890-909.	0.4	42
180	Galectin-3 as a Predictor of Left Ventricular Reverse Remodeling in Recent-Onset Dilated Cardiomyopathy. <i>Disease Markers</i> , 2018, 2018, 1-7.	0.6	9
181	Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 976.	1.8	52

#	ARTICLE	IF	CITATIONS
182	Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. <i>Theranostics</i> , 2018, 8, 4155-4169.	4.6	68
183	Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. <i>Scientific Reports</i> , 2018, 8, 8213.	1.6	42
184	Heart failure with preserved ejection fraction: from mechanisms to therapies. <i>European Heart Journal</i> , 2018, 39, 2780-2792.	1.0	250
185	Cystatin C and galectin-3 as therapeutic targets in heart failure. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2018, 12, 233-235.	1.0	3
186	Clinical Trials and Applications of Galectin Antagonists. <i>Trends in Glycoscience and Glycotechnology</i> , 2018, 30, SE211-SE220.	0.0	35
187	Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. <i>Molecular Aspects of Medicine</i> , 2019, 65, 70-99.	2.7	538
188	Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 736-745.e6.	1.5	123
189	Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2305-2318.	2.3	20
190	Galectin-3 as a candidate upstream biomarker for quantifying risks of myocardial ageing. <i>ESC Heart Failure</i> , 2019, 6, 1068-1076.	1.4	15
191	The guanylate cyclase C agonist linacotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 250-264.	0.4	35
192	Biomarkers Associated with Atrial Fibrosis and Remodeling. <i>Current Medicinal Chemistry</i> , 2019, 26, 780-802.	1.2	16
193	Blood Galectin-3 Levels Predict Postoperative Complications after Colorectal Cancer Surgery. <i>Journal of Nippon Medical School</i> , 2019, 86, 142-148.	0.3	7
194	Negative Risk Markers for Cardiovascular Events in the Elderly. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1-11.	1.2	71
195	Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition. <i>Scientific Reports</i> , 2019, 9, 9607.	1.6	35
196	Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets to Prevent Cardiovascular Remodeling. , 0, , .		2
197	Pleiotropic Effects of Modified Citrus Pectin. <i>Nutrients</i> , 2019, 11, 2619.	1.7	68
198	Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3 β . <i>Circulation</i> , 2019, 140, 1188-1204.	1.6	62
199	Cardioprotective effects of galectin-3 inhibition against ischemia/reperfusion injury. <i>European Journal of Pharmacology</i> , 2019, 863, 172701.	1.7	15

#	ARTICLE	IF	CITATIONS
200	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 272-285.	2.9	182
201	Biomarkers in heart failure: the past, current and future. <i>Heart Failure Reviews</i> , 2019, 24, 867-903.	1.7	87
202	The relationship between galectin-3 levels and fragmented QRS (fQRS) in patients with heart failure with reduced left ventricular ejection fraction. <i>Annals of Noninvasive Electrocardiology</i> , 2019, 24, e12671.	0.5	8
203	Galectin-3 Levels and Outcomes After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2286-2295.	1.2	46
204	Left Ventricular Fibrosis in Patients with Aortic Stenosis. , 2019, , 127-139.		0
205	Collagen. <i>Methods in Molecular Biology</i> , 2019, , .	0.4	5
206	Procollagen C-Proteinase Enhancer 1 (PCPE-1) in Liver Fibrosis. <i>Methods in Molecular Biology</i> , 2019, 1944, 189-201.	0.4	4
207	Right ventricular pressure overload alters cardiac lipid composition. <i>International Journal of Cardiology</i> , 2019, 287, 96-105.	0.8	8
208	Mechanisms of cardiac collagen deposition in experimental models and human disease. <i>Translational Research</i> , 2019, 209, 138-155.	2.2	51
209	Stimulation of β_2 -adrenoceptors up-regulates cardiac expression of galectin-3 and <i>BIM</i> through the <i>Hippo</i> signalling pathway. <i>British Journal of Pharmacology</i> , 2019, 176, 2465-2481.	2.7	29
210	Sleep apnea and galectin-3: possible sex-specific relationship. <i>Sleep and Breathing</i> , 2019, 23, 1107-1114.	0.9	8
211	Galectin-3 in Acute Myocardial Infarction Patients with Atrial Fibrillation. <i>Medical Principles and Practice</i> , 2019, 28, 284-290.	1.1	16
212	Galectin-3: A Harbinger of Reactive Oxygen Species, Fibrosis, and Inflammation in Pulmonary Arterial Hypertension. <i>Antioxidants and Redox Signaling</i> , 2019, 31, 1053-1069.	2.5	29
213	β_2 -Adrenoceptor activation affects galectin-3 as a biomarker and therapeutic target in heart disease. <i>British Journal of Pharmacology</i> , 2019, 176, 2449-2464.	2.7	20
214	Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure. <i>Disease Markers</i> , 2019, 2019, 1-8.	0.6	1
215	Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling. <i>Scientific Reports</i> , 2019, 9, 18765.	1.6	27
216	Disconnect between Fibrotic Response and Right Ventricular Dysfunction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1550-1560.	2.5	34
217	Biomarkers to Assess and Guide the Management of Heart Failure. , 2019, , 97-108.		0

#	ARTICLE	IF	CITATIONS
218	Differential Prognostic Value of Galectin-3 According to Carbohydrate Antigen 125 Levels in Transcatheter Aortic Valve Implantation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 907-915.	0.4	4
219	Echocardiographic diastolic function evolution in patients with an anterior <sc>Q</sc> wave myocardial infarction: insights from the <sc>REVE</sc> study. <i>ESC Heart Failure</i> , 2019, 6, 70-79.	1.4	4
220	Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2019, 316, H45-H60.	1.5	47
221	Galectin-3 and risk of cardiovascular events and all-cause mortality in type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3093.	1.7	18
222	The role of galectin-3 in heart failure and cardiovascular disease. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 197-203.	0.9	60
223	Galectin-3 exacerbates oxLDL-mediated endothelial injury by inducing inflammation via integrin β_1 -RhoA/JNK signaling activation. <i>Journal of Cellular Physiology</i> , 2019, 234, 10990-11000.	2.0	36
224	Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 41-63.	4.2	23
225	Ascorbic Acid Promotes Procollagen α 1(I) Expression, Secretion, and Cell Membrane Localization. <i>Anatomical Record</i> , 2020, 303, 1670-1679.	0.8	5
226	sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. <i>Acta Cardiologica</i> , 2020, 75, 739-747.	0.3	12
227	Gal-3 (Galectin-3) and $K_{Ca}3.1$ Mediate Heterogeneous Cell Coupling and Myocardial Fibrogenesis Driven by β_2 AR (β_2 -Adrenoceptor) Activation. <i>Hypertension</i> , 2020, 75, 393-404.	1.3	16
228	Role of oxidative stress-related biomarkers in heart failure: galectin 3, β_1 -antitrypsin and LOX-1: new therapeutic perspective?. <i>Molecular and Cellular Biochemistry</i> , 2020, 464, 143-152.	1.4	35
229	Value of Galectin-3 in Acute Myocardial Infarction. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 333-342.	1.0	20
230	Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. <i>American Heart Journal</i> , 2020, 220, 253-263.	1.2	10
231	Emerging biomarkers for cardiac arrhythmias. <i>Clinical Biochemistry</i> , 2020, 75, 1-6.	0.8	10
232	Current Understanding of the Biomechanics of Ventricular Tissues in Heart Failure. <i>Bioengineering</i> , 2020, 7, 2.	1.6	21
233	Roles of Biomarkers in Myocardial Fibrosis. , 2020, 11, 1157.		27
234	Galectin-3 and soluble ST2 as complementary tools to cardiac MRI for sudden cardiac death risk stratification in heart failure: A review. <i>JRSM Cardiovascular Disease</i> , 2020, 9, 204800402095784.	0.4	6
235	Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes. <i>Biomarkers in Medicine</i> , 2020, 14, 943-954.	0.6	8

#	ARTICLE	IF	CITATIONS
236	Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity. <i>Scientific Reports</i> , 2020, 10, 16682.	1.6	9
237	Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure. <i>Journal of Clinical Medicine</i> , 2020, 9, 2229.	1.0	17
238	Evolution of blood biomarker levels following percutaneous atrial septal defect closure in adults. <i>IJC Heart and Vasculature</i> , 2020, 30, 100582.	0.6	3
239	Insight into the Pro-inflammatory and Profibrotic Role of Macrophage in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 276-285.	0.8	9
240	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. <i>Cardiovascular Research</i> , 2021, 117, 2108-2124.	1.8	108
241	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. <i>EMBO Molecular Medicine</i> , 2020, 12, e10865.	3.3	104
242	Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials. <i>Cardiology and Therapy</i> , 2020, 9, 363-376.	1.1	35
243	Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction. <i>Journal of Laboratory Physicians</i> , 2020, 12, 126-132.	0.4	11
244	Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5689.	1.8	9
245	Galectin-3 in Cardiovascular Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9232.	1.8	82
246	Genetic Deletion of Galectin-3 Alters the Temporal Evolution of Macrophage Infiltration and Healing Affecting the Cardiac Remodeling and Function after Myocardial Infarction in Mice. <i>American Journal of Pathology</i> , 2020, 190, 1789-1800.	1.9	16
247	Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection. <i>Cell Systems</i> , 2020, 11, 11-24.e4.	2.9	439
248	Cardiovascular Consequences of Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2020, 382, 2238-2247.	13.9	88
249	MicroRNA-27 attenuates pressure overload-induced cardiac hypertrophy and dysfunction by targeting galectin-3. <i>Archives of Biochemistry and Biophysics</i> , 2020, 689, 108405.	1.4	14
250	Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. <i>Disease Markers</i> , 2020, 2020, 1-21.	0.6	57
251	Inflammation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1324-1340.	1.2	273
252	Galectin-3 Is a Potential Mediator for Atherosclerosis. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	62
254	Levels and Change in Galectin-3 and Association With Cardiovascular Events: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e015405.	1.6	15

#	ARTICLE	IF	CITATIONS
255	Anti-inflammatory Role of Galectin-8 During Trypanosoma cruzi Chronic Infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 285.	1.8	7
256	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. <i>PLoS ONE</i> , 2020, 15, e0232507.	1.1	21
257	Effect of pulmonary vein catheter ablation on kidney function in patients with atrial fibrillation. A prospective cohort study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 471-478.	0.4	1
258	Tolerogenic Dendritic Cells Reduce Cardiac Inflammation and Fibrosis in Chronic Chagas Disease. <i>Frontiers in Immunology</i> , 2020, 11, 488.	2.2	22
259	Galectin-3 Identifies a Subset of Macrophages With a Potential Beneficial Role in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 1491-1509.	1.1	49
260	Stretch-induced sarcoplasmic reticulum calcium leak is causatively associated with atrial fibrillation in pressure-overloaded hearts. <i>Cardiovascular Research</i> , 2021, 117, 1091-1102.	1.8	27
261	The therapeutic potential of galectin-3 inhibition in fibrotic disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 130, 105881.	1.2	67
262	Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H432-H446.	1.5	20
263	Cardiac fibrosis. <i>Cardiovascular Research</i> , 2021, 117, 1450-1488.	1.8	419
264	Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (⁸⁹ Zr)-DFO- Galectin3-F(ab') ₂ mAb. <i>Theranostics</i> , 2021, 11, 1864-1876.	4.6	16
265	Biomarkers. , 2021, , 31-64.		0
266	Epicardial Adiposity in Relation to Metabolic Abnormality, Circulating Adipocyte FABP, and Preserved Ejection Fraction Heart Failure. <i>Diagnostics</i> , 2021, 11, 397.	1.3	5
267	Plasma Galectin-3 is associated with progression from paroxysmal to persistent atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 226.	0.7	6
268	Right ventricular diastolic dysfunction and failure: a review. <i>Heart Failure Reviews</i> , 2022, 27, 1077-1090.	1.7	6
269	Galectin-3 participates in PASMC migration and proliferation by interacting with TGF- β 1. <i>Life Sciences</i> , 2021, 274, 119347.	2.0	8
270	Role of novel biomarkers in diabetic cardiomyopathy. <i>World Journal of Diabetes</i> , 2021, 12, 685-705.	1.3	19
271	Current Use of Cardiac Biomarkers in Various Heart Conditions. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 980-993.	0.6	12
272	Small Endogeneous Peptide Mitigates Myocardial Remodeling in a Mouse Model of Cardioslective Galectin-3 Overexpression. <i>Circulation: Heart Failure</i> , 2021, 14, e008510.	1.6	8

#	ARTICLE	IF	CITATIONS
273	Therapeutic Potential of Galectin-1 and Galectin-3 in Autoimmune Diseases. <i>Current Pharmaceutical Design</i> , 2022, 28, 36-45.	0.9	4
274	The Utility of Circulating and Imaging Biomarkers Alone and in Combination in Heart Failure. <i>Current Cardiology Reviews</i> , 2021, 17, e160721193557.	0.6	1
275	Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2021, 14, e008532.	1.6	17
276	Galectin-3: A simple tool for a complex clinical issue?. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 837-837.	0.2	1
277	Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
278	Galectin-3 Promotes ROS, Inflammation, and Vascular Fibrosis in Pulmonary Arterial Hypertension. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1303, 13-32.	0.8	12
279	Research progress on the role of gal-3 in cardio/cerebrovascular diseases. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111066.	2.5	9
280	Serum Galectin-3 and Subsequent Risk of Coronary Heart Disease in Subjects With Childhood-Onset Type 1 Diabetes: A Cohort Study. <i>Diabetes Care</i> , 2021, 44, 810-816.	4.3	9
282	Efecto de la ablaci3n con cat3ter de venas pulmonares en la funci3n renal de pacientes con fibrilaci3n auricular. Estudio de cohortes prospectivo. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 471-478.	0.6	1
285	Cardiac Function and Architecture Are Maintained in a Model of Cardioresstricted Overexpression of the Prorenin-Renin Receptor. <i>PLoS ONE</i> , 2014, 9, e89929.	1.1	12
286	Prognostic Value of the Interaction between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure. <i>PLoS ONE</i> , 2015, 10, e0122360.	1.1	18
287	Inhibition of Interleukin-6 Receptor in a Murine Model of Myocardial Ischemia-Reperfusion. <i>PLoS ONE</i> , 2016, 11, e0167195.	1.1	39
288	Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. <i>PLoS ONE</i> , 2017, 12, e0177242.	1.1	25
289	Galectin-3 Serum Levels Are Independently Associated With Microalbuminuria in Chronic Heart Failure Outpatients. <i>Research in Cardiovascular Medicine</i> , 2015, 5, e28952.	0.2	19
290	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3. <i>Revista Portuguesa De Cardiologia</i> , 2021, 40, 829-829.	0.2	7
291	Combination of Fibrotic Markers accurately predict liver fibrosis in Hepatitis C Patients. <i>Biochemistry Letters</i> , 2018, 13, 180-186.	0.1	0
292	Galectin-3 and Fibrosis: Research in the Last 5 Years. <i>Journal of Translational Critical Care Medicine</i> , 2019, 1, 117-126.	0.0	3
293	Expression of microRNA214 and galectin3 in peripheral blood of patients with chronic heart failure and its clinical significance. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1322-1328.	0.8	6

#	ARTICLE	IF	CITATIONS
295	Antiarrhythmic Properties of Non-Antiarrhythmic Drugs in Atrial Fibrillation: Upstream Therapy. , 2020, , 307-377.		0
296	High-sensitivity Troponin I Predicts Galectin-3 in Chronic Kidney Disease Patients. International Urology and Nephrology, 2020, 52, 533-540.	0.6	1
298	Galectin-3 levels and the prediction of atrial high-rate episodes in patients with cardiac resynchronization therapy. Journal of Investigative Medicine, 2021, 69, 20-27.	0.7	3
299	ST2 and Galectin-3: Ready for Prime Time?. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2016, 27, 238-52.	0.7	18
300	Pectins from various sources inhibit galectin-3-related cardiac fibrosis. Current Research in Translational Medicine, 2022, 70, 103321.	1.2	2
301	A new biomarker that predicts ventricular arrhythmia in patients with ischemic dilated cardiomyopathy: Galectin-3. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 829-835.	0.2	3
302	Galectin-3: A simple tool for a complex clinical issue?. Revista Portuguesa De Cardiologia (English) Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50	0.2	0
303	Therapeutic implications of galectin-3 in patients with atrial fibrillation. Scientific Reports, 2022, 12, 784.	1.6	6
304	Modification of Serum Galectin-3 and Reversal of Cardiac Remodeling Following Pediatric Transcatheter Atrial Septal Defect Closure. Congenital Heart Disease, 2022, 17, 173-185.	0.0	0
305	Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats. Clinical and Molecular Hepatology, 2022, 28, 232-241.	4.5	6
306	Integrated Liver and Plasma Proteomics in Obese Mice Reveals Complex Metabolic Regulation. Molecular and Cellular Proteomics, 2022, 21, 100207.	2.5	12
307	Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2021, 8, 829151.	1.1	4
308	Galectins. , 2022, , 557-584.		0
309	Chronic kidney disease predictors in obese adolescents. Pediatric Nephrology, 2022, 37, 2479-2488.	0.9	6
310	Prognostic Value of Serum Galectin-3 in Chronic Heart Failure: A Meta-Analysis. Frontiers in Cardiovascular Medicine, 2022, 9, 783707.	1.1	8
311	Methods of in vitro study of galectin-glycomaterial interaction. Biotechnology Advances, 2022, 58, 107928.	6.0	10
312	The predictive value of galectin-3 levels on left atrial low voltage areas assessed by high-density mapping in patients with paroxysmal atrial fibrillation. Journal of Arrhythmia, 2022, 38, 353-362.	0.5	1
313	An overview about galectin-3 and its relationship with cardiovascular diseases. Journal of Surgery and Medicine, 2021, 5, 1218-1220.	0.0	1

#	ARTICLE	IF	CITATIONS
314	The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. <i>Biomolecules</i> , 2022, 12, 46.	1.8	28
315	Exploring the Causal Effects of Circulating ST2 and Galectin-3 on Heart Failure Risk: A Mendelian Randomization Study. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 868749.	1.1	1
316	Galectin-3 interferes with tissue repair and promotes cardiac dysfunction and comorbidities in a genetic heart failure model. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 250.	2.4	10
319	Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 908-951.	0.2	6
320	Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023238.	1.6	8
321	Long-term Dexamethasone Treatment Increases Cardiac Galectin-3 Levels. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	1.3	3
322	Biomarkers of Myocardial Injury and Remodeling in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 799.	1.1	13
323	Galectin-3 Inhibition Ameliorates Streptozotocin-Induced Diabetic Cardiomyopathy in Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 868372.	1.1	7
325	Galectin-3 is an independent predictor of postoperative atrial fibrillation and survival after elective cardiac surgery. <i>Heart Rhythm</i> , 2022, 19, 1774-1780.	0.3	2
326	The Role of Circulating Collagen Turnover Biomarkers and Late Gadolinium Enhancement in Patients with Non-Ischemic Dilated Cardiomyopathy. <i>Diagnostics</i> , 2022, 12, 1435.	1.3	4
327	Biomarkers in Heart Failure with Preserved Ejection Fraction. <i>Cardiac Failure Review</i> , 0, 8, .	1.2	16
328	The Atrium in Atrial Fibrillation – A Clinical Review on How to Manage Atrial Fibrotic Substrates. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	14
329	Multimodal Approach for the Prediction of Atrial Fibrillation Detected After Stroke: SAFAS Study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	10
330	Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment. <i>Life</i> , 2022, 12, 1111.	1.1	22
331	Research Progress of Myocardial Fibrosis and Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
332	Sex-specific associations of cardiorespiratory fitness and galectin-3 in the general population. <i>ESC Heart Failure</i> , 2022, 9, 4240-4249.	1.4	4
333	The emerging role of leptin in obesity-associated cardiac fibrosis: evidence and mechanism. <i>Molecular and Cellular Biochemistry</i> , 2023, 478, 991-1011.	1.4	4
334	Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?. <i>Current Heart Failure Reports</i> , 2022, 19, 400-411.	1.3	9

#	ARTICLE	IF	CITATIONS
335	Association between Endothelial Cell-Specific Molecule 1 and Galectin-3 in Patients with ST-Segment Elevation Myocardial Infarction: A Pilot Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-6.	1.9	1
336	Inhibition of Galectin-3 attenuates silica particles-induced silicosis via regulating the GSK-3 β / β -catenin signal pathway-mediated epithelial-mesenchymal transition. <i>Chemico-Biological Interactions</i> , 2022, 368, 110218.	1.7	3
337	The interplay of galectins-1, -3, and -9 in the immune-inflammatory response underlying cardiovascular and metabolic disease. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	8
338	Galectin-3-centered paracrine network mediates cardiac inflammation and fibrosis upon β -adrenergic insult. <i>Science China Life Sciences</i> , 2023, 66, 1067-1078.	2.3	8
339	Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
340	Experimental heart failure models in small animals. <i>Heart Failure Reviews</i> , 0, , .	1.7	0
341	New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside and Back. <i>Biomedicines</i> , 2023, 11, 70.	1.4	1
342	Plasma Galectin-3 and H-FABP correlate with poor physical performance in patients with congestive heart failure. <i>Experimental Biology and Medicine</i> , 2023, 248, 532-540.	1.1	3
343	Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction. <i>Pharmaceutics</i> , 2023, 15, 729.	2.0	1
344	Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure. <i>Biomolecules</i> , 2023, 13, 410.	1.8	4
345	Cellular environment of TTR deposits in an animal model of ATTR β Cardiomyopathy. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	0
346	Cardiac System during the Aging Process. , 2023, .		3
347	Galectin-3 as a Novel Biomarker of Cardiovascular Disease. <i>Angiology</i> , 0, , 000331972311700.	0.8	1
348	Coronary Artery Spasm-Related Heart Failure Syndrome: Literature Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7530.	1.8	2
361	Do Heart Failure Biomarkers Influence Heart Failure Treatment Response?. <i>Current Heart Failure Reports</i> , 2023, 20, 358-373.	1.3	0